Clinical trial
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
NCT01621178
Study timeline
Study start (unknown)2012-07-01Date precision: month
Registry last updated2019-09-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetesunresolved
Chronic Kidney Diseaseunresolved
Interventions
DulaglutideDRUG · verified · RxNorm: dulaglutide
Insulin glargineDRUG · verified · RxNorm: insulin glargine
Insulin lisproDRUG · verified · RxNorm: insulin lispro
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
MiamiFlorida, United States4HoustonTexas, United States3Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1San AntonioTexas, United States1BarcelonaSpain1PittsburghPennsylvania, United States1JacksonvilleFlorida, United States1AustinTexas, United States1BudapestHungary1ValenciaSpain1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01621178 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.